EMMA VIENNA – Preliminary Program

Thursday, January 27, 2022


WELCOME EDUCATIONAL DINNER BUFFET

19.00 Buffet opening

19.30-19.50 DIFFICULT DECISIONS IN MYELOMA MANAGEMENT: When to initiate therapy in different settings, how to monitor disease (including non-secretory, extramedullary, and LC myeloma) and indications for `old type chemotherapy.
Mario Boccadoro

 

Friday, January 28, 2022


8.30-8.40 Opening 
Heinz Ludwig and Jesús F. San-Miguel

 

MYELOMA BIOLOGY AND RISK STRATIFICATION     

8.40-9.00 Molecular events in the pathogenesis of myeloma 
Niccolò Bolli

9.00-9.20 Epigenetic and environmental factors in the pathogenesis of MM
Charlotte Pawlyn

9.20-9.40 Genetic risk classification of multiple myeloma
Hervé Avet-Loiseau

9.40-10.10 Discussion around important questions
    •    Role of genetic predisposition for MM
    •    Has the time come for a new classification of MM
    •    Has the time come for revision of risk factors
    •    Are epigenetic compounds underused
    •    Options for modulation of the immune environment

 

10.10-10.30 BREAK

 

NOVEL DEVELOPMENTS IN DISEASE AND RESPONSE ASSESSMENT

10.30-10.50 The role of MRD
Bruno Paiva

10.50-11.10 Advances in imaging in MM including diffusion-weighted MRI
Martin Kaiser 

11.10-11.30 Mass spectrometry for diagnosis and prognostication
Noemi Puig

11.30-12.00 Discussion around important questions
    •    Requirements of regulatory agencies for approving MRD 
    •    Circulating plasma cells for disease and response assessment
    •    Optimizing imaging technologies – MRI and PET/CT
    •    Impact of higher M-protein detection sensitivity (MGUS and MRD)
    •    MRD assessment and MGUS-like MM

 

WORKSHOPS

12.00-12.45 Detection, prevention and treatment of bone disease
Evangelos Terpos

12.00-12.45 Management of patients with solitary plasmacytoma, extramedullary myeloma and plasma cell leukemia
Kwee Yong

 

12.45- 13.45 LUNCH

 

MANAGEMENT OF PATIENTS WITH SMOLDERING AND TRANSPLANT ELIGIBLE DISEASE

13.45-14.05 Smoldering MM. Present definition and approaches and a glance into the future
Maria-Victoria Mateos

14.05-14.25 Frontline therapy in TE patients
Philippe Moreau

14.25-14.45 Expanding opportunities for maintenance treatment
Michele Cavo

14.45-15.15 Discussion around important questions
    •    Delaying ASCT yields similar survival as upfront ASCT. Why is this principle different in SMM
    •    Any ideas how to further improve prediction of progression to >90% within one year?
    •    What is the optimal number of induction and consolidation cycles?
    •    MRD guide therapy ready for prime time
    •    Maintenance therapy tomorrow

 

15.15-15.35 BREAK

 

MANAGEMENT OF TRANSPLANT INELIGIBLE PATIENTS

15:35-15:55 Advances in the treatment of transplant-ineligible patients
Thierry Facon

15:55-16.15 Assessment of frailty and management of frail patients
Alessandra Larocca

16.15-16.45 Discussion of important questions
    •    Initiation of therapy at biochemical progression
    •    Treatment duration
    •    Impact of individual risk on treatment selection
    •    Supportive care issues
    •    Treatment of very elderly patients

 

16.45-17.30 WORKSHOPS (repeated)

 

KEYNOTE LECTURE

17.30-18.00 Cure is the goal: Progress in multiple myeloma
Jesús San-Miguel

 

 

Saturday, January 29, 2022


THE BEST APPROACH TO PATIENTS WITH RELAPSED/REFRACTORY DISEASE

8.30-8.50 How to select therapy after relapse to one or two prior treatment lines
Pieter Sonneveld

8.50-9.10 Hard to treat relapsed/Refractory patients
Mohamad Mohty

9.10-9.30 Recently approved new drugs (Blenrep, Selinexor, Melflufen)
Fredrik Schjesvold

9.30-10.00 Discussion of important questions
    •    Early relapse
    •    Lenalidomide refractory patients
    •    CD38 retreatment

 

10.00-10.20 BREAK

 

HOT TOPICS IN MYELOMA

10.20-10.40 COVID
Heinz Ludwig

10.40-11.00 BiTEs-and monoclonal antibodies
Niels van de Donk

11.00-11.20 CAR-T cells and other cellular therapies
Hermann Einsele

11.20-11.50 Discussion of important questions
    •    Options for COVID vaccination non-responders
    •    Improving tolerance of novel treatments
    •    BiTEs or cellular therapies
    •    Combination of novel drugs/treatment approaches

 

OTHER IMPORTANT DISEASES

11.50-12.10 New developments in the management of Amyloidosis
Giampaolo Merlini

12.10-12.30 New developments in the management of Waldenström’s disease
Meletios A. Dimopoulos

12.30-12.45 Discussion of important questions
    •    Is cure a realistic goal in amyloidosis?
    •    Cellular therapies in amyloidosis
    •    Treatment of patients failing to first-line treatment with PTK inhibitors and CD20+ base therapies 
    •    Should anti-BCMA treatments be explored in Waldenström’s disease as 2/3 express BCMA on their tumor clones?

 

12.45-12.50 Closure of the meeting